ストックスクリーナーアプリを入手
33.92
1.22%
0.41
前日終値:
$33.51
開ける：
$33.5
24時間の取引高:
45,916
Relative Volume:
0.60
時価総額：
$1.54B
収益：
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
+11.25%
1か月 パフォーマンス:
+29.47%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$29.93
$35.34
52週間の値動き範囲:
$21.00
$37.27
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Company Profile
Compare KRSA vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRSA
Korsana Biosciences, Inc. Common Stock
|
33.92 | 1.54B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-05 | 開始されました | Wedbush | Outperform |
| 2026-09-28 | 開始されました | Guggenheim | Buy |
| 2026-09-14 | 開始されました | Stifel | Buy |
| 2026-09-14 | 開始されました | TD Cowen | Buy |
| 2026-09-11 | 開始されました | UBS | Buy |
| 2021-10-20 | 開始されました | Truist | Buy |
| 2021-09-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Korsana Biosciences, Inc. Common Stock (KRSA) 最新ニュース
A passive stake above 5% in Korsana Biosciences (KRSA) is reported by FMR LLC in an amendment. - Stock Titan
Korsana Biosciences (NASDAQ: KRSA) director to sell 100 more shares after 2,139 sold recently - Stock Titan
After two September sales, a Korsana Biosciences (KRSA) director proposes selling 4,903 more shares. - Stock Titan
General Atlantic’s stake in Korsana (CYCN) comes with a strict ownership cap - Stock Titan
Korsana Biosciences (CYCN) director proposes $74.8K stock sale - Stock Titan
A fund reports a 6.1% passive stake in Korsana Biosciences (CYCN), with the investor's identity detailed in the filing. - Stock Titan
Nearly 10% of Korsana Biosciences (CYCN) is tied to one investor group, but its ownership is capped below that line. - Stock Titan
Diluted net income available to common stockholders of Korsana Biosciences, Inc. – NASDAQ:KRSA - TradingView
Korsana Biosciences, Inc. Statistics – NASDAQ:KRSA - TradingView
Investor gains significant stake and board power at Korsana Biosciences (CYCN) - Stock Titan
Korsana Biosciences, Inc. (KRSA) Company Information - Simply Wall Street
Why a 9.99% cap now limits a key Korsana (CYCN) holder - Stock Titan
CFO option stakes detailed at Korsana Biosciences (CYCN) after merger - Stock Titan
Merger gives Korsana Biosciences (CYCN) CMO options expiring in 2036 - Stock Titan
Korsana Biosciences (CYCN) director holds merger-issued option - Stock Titan
New Korsana Biosciences (CYCN) director reports 28,805-share option - Stock Titan
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million - The Manila Times
CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline - International Business Times Australia
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com
Cyclerion Therapeutics and Korsana Biosciences To Merge - citybiz
Cyclerion Therapeutics and Korsana Biosciences to merge - The Pharma Letter
CYCN Merges with Korsana Biosciences for Strategic Growth - GuruFocus
Korsana Biosciences, Inc. Common Stock (KRSA) 財務データ
Korsana Biosciences, Inc. Common Stock (KRSA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Korsana Biosciences, Inc. Common Stock (KRSA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ERROL B DE SOUZA | Director |
Sep 22 '26 |
Proposed Sale |
34.99 |
100 |
3,499 |
0 |
| ERROL B DE SOUZA | Director |
Sep 18 '26 |
Proposed Sale |
34.99 |
2,139 |
74,844 |
0 |
| CHICKO RHONDA M. | Chief Financial Officer |
Aug 14 '26 |
Option Exercise |
2.35 |
25,000 |
58,875 |
25,018 |
| Graul Regina Margaret | See Remarks |
Aug 14 '26 |
Option Exercise |
3.30 |
55,849 |
184,302 |
156,152 |
1.63%
大文字化:
|
ボリューム (24 時間):